Northwire Canada EditionSunday, July 12, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Production / Operations

Terumo Launches SurTract(TM) Safety Syringe in the United States, Powered by Roncadelle Operations' SafeR(TM) Passive Safety Technology

4543 · Price

Executive Summary

  • Terumo Medical Corporation announced the U.S. launch of its new SurTract™ Safety Syringe, incorporating Roncadelle Operations’ SafeR® passive safety technology.
  • The syringe features an automatic needle‑retraction mechanism, customizable blunt needles, reduced medical waste, and low dead‑space design to minimize medication waste.
  • Distribution will begin across hospitals, clinics, and emergency‑care settings in Q1 2026.

Key Details

  • Product: SurTract™ Safety Syringe – a retractable safety hypodermic syringe powered by SafeR® passive safety technology.
  • Technology: SafeR® provides fully passive, automatic needle retraction into the plunger immediately after use, reducing needle‑stick injuries and improving patient comfort.
  • Key Benefits:
  • Customizable blunt‑needle selection for optimal clinical use.
  • Elimination of external plastic safety sheath → less medical waste.
  • Low dead‑space design → reduced medication waste.
  • Launch Timeline: Distribution in the United States to begin in the first quarter of 2026 across hospitals, clinics, and emergency‑care settings.
  • Quotes:
  • Bob Klock, Vice President, Terumo Medical Corporation – “The SurTract Syringe combines Terumo's trusted clinical know‑how with Roncadelle's validated SafeR technology to deliver a simple, effective solution for safer injections.”
  • Dr. Fred Metzmann, Chief Business Development Officer, Roncadelle Operations – “Terumo has significantly advanced injection safety with the integration of our SafeR technology… delivering a next‑generation syringe system that is intuitive, reliable, and engineered to protect healthcare professionals.”

Notable Quotes

  • “It gives healthcare providers more – and better – treatment options for their patients, which is our ultimate goal.” – Bob Klock, VP, Terumo Medical Corporation
  • “Together, we are delivering a next‑generation syringe system that is intuitive, reliable, and engineered to protect healthcare professionals.” – Dr. Fred Metzmann, Roncadelle Operations
Read the original news release →

More from None